Form 4: Equillium Director Barbara Troupin Granted 20,000 Stock Options

Equillium, Inc. Director Barbara Troupin was granted 20,000 stock options with an exercise price of $0.39, aligning her interests with shareholders.

Summary

• Barbara Troupin, a Director of Equillium, Inc. (EQ), was granted 20,000 Director Stock Options on May 21, 2025.
• Each option grants the right to buy one share of Common Stock.
• The exercise price for these options is $0.39 per share.
• The options will vest in twelve equal monthly installments, commencing on the grant date of May 21, 2025.
• The options will be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
• The expiration date for these options is May 20, 2035.
• Following this transaction, Barbara Troupin beneficially owns 20,000 derivative securities (options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The grant of stock options to a director aligns their financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period, providing a long-term incentive horizon.

Future Outlook

The granted stock options will vest over the next twelve months, or fully upon the next annual stockholders' meeting, providing a future incentive for the director.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent and align management and board interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like Equillium.
• The vesting schedule (monthly over 12 months or full vesting at the next annual meeting) is a typical structure for such equity grants, designed to retain directors and incentivize performance over time.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options from Equillium, Inc. to Barbara Troupin, a Director of the company. This is considered a related party transaction, though it is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.

Next Steps

• The granted options will continue to vest according to the specified schedule.
• The director may choose to exercise the vested options at any point before their expiration date.

Key Dates

Recommendation

Keywords

Equillium, EQ, Form 4, Insider Transaction, Stock Option, Director Compensation, Beneficial Ownership, Equity Grant